AAR Corp posted robust Q1 results with $918 million in sales and a 12.7% adjusted EBITDA margin, showing a 24% sales increase year-over-year. The company is acquiring a 65% stake in MRO Holdings, expected to add over $1 billion in revenue and raise EBITDA margins to 16%. Despite these positives, the stock fell due to investor worries about new debt amid rising interest rates. Analysts remain optimistic, raising the price target to $160, signaling confidence in AAR's growth and strategic moves.
AAR Corp's recent Q1 growth and MRO acquisition news provide context for industrial sector trends. For readers following Industrials, here is Pluang's market snapshot as of Sep 30, 2026 03:11 WIB: Among 93 priced US industrial stocks, 45 rose and 48 fell. Notable movers include Enovix Corporation (ENVX) up 8.02% at USD 2.76 with 57% buy orders, Boeing Co (BA) down 6.39% at USD 185.41 with 62% buy orders, and SMX Security Matters plc (SMX) up 5.28% at USD 7.18 with 64% buy orders.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
